Skip to main content

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Periodic Reporting for period 1 - QTB4AMR (Utilizing an innovative chemical platform to defeat antimicrobial resistance)

Période du rapport: 2019-08-01 au 2020-01-31

The overall objective of QureTech Bio AB is to tackle the challenges posed by the emergence of antimicrobial resistance (AMR) with a conceptually new approach – restoring the effectiveness of standard-of-care antibiotics. We have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). Our compounds sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. By circumventing the painstaking process of discovering and developing new antibiotics, we bring forth a more cost-effective approach to confront the emergence of AMR. Allowing pharmaceutical companies to protect decades worth of R&D efforts and billions of euros in development costs, we present them with an attractive value proposition. Society will benefit by getting access to antibiotics previously being non-functional due to antibiotic resistance. Our platform enables the fast, high-yield production of ARBs against gram-positive bacteria (GmPcides). Our compounds have displayed effectiveness against two of the most threatening drug-resistant pathogens MRSA and VRE. Moreover, the compounds exhibit a strong in vivo synergy with two of the world’s most essential antibiotics Gentamicin and Vancomycin. During the feasibility project, we developed a scalable business plan that will guide QureTech Bio AB in development and commercializing of our compounds.
The project involved a comprehensive analysis of epidemiological and market data, investigation of competitive landscape and market barriers, assessing user needs, financial requirements, IPR strategy and developing a commercialization plan. During the clinical feasibility study we identified the target indication for our compounds, outlined the plan for further development towards clinical trials as well as to identified potential partners for preclinical development. The feasibility study has confirmed that QureTech Bio’s GmPcide demonstrates a strong commercial and clinical viability.
At Quretech Bio AB, we have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). These ARBs sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. Our platform enables the fast, high-yield production of ARBs against Gram-positive bacteria (GmPcides). By circumventing the notably difficult process of discovering and developing new antibiotics, our approach constitutes a faster and more cost-effective strategy to confront the emergence of AMR. Quretech’s ARBs present the healthcare system and pharmaceutical industry with an attractive value proposition. The former will benefit from revitalising their antibiotics inventory and controlling the spiralling costs of untreatable infections. The latter will have the opportunity of protecting decades worth of R&D efforts and EUR billions invested in developing antibiotics.
quretech-logo.jpg